AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience PipelinePRNewsWire • 10/05/23
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer ImmunotherapyPRNewsWire • 10/04/23
3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 YearsThe Motley Fool • 10/04/23
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsBusiness Wire • 10/02/23
Dividend Growth Predictions For 15 Companies Announcing Annual Boosts In OctoberSeeking Alpha • 10/02/23
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple MyelomaPRNewsWire • 09/29/23
Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 YearsThe Motley Fool • 09/29/23
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?Zacks Investment Research • 09/28/23
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell LymphomaPRNewsWire • 09/25/23
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementBusiness Wire • 09/22/23